Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Average PT from Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $55.06.

Several equities analysts have recently commented on KYMR shares. UBS Group reduced their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. BTIG Research began coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Truist Financial reiterated a “buy” rating and issued a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Stephens reiterated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Finally, Guggenheim increased their target price on Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $39.40 on Thursday. The company has a 50 day simple moving average of $42.56 and a two-hundred day simple moving average of $44.83. The firm has a market cap of $2.55 billion, a PE ratio of -16.84 and a beta of 2.19. Kymera Therapeutics has a 1 year low of $29.24 and a 1 year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter in the prior year, the firm earned ($0.90) earnings per share. The firm’s revenue was down 20.9% on a year-over-year basis. As a group, research analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Blue Trust Inc. boosted its holdings in Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Kymera Therapeutics by 1.7% in the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock worth $1,649,000 after purchasing an additional 684 shares in the last quarter. KBC Group NV grew its position in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after purchasing an additional 752 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Kymera Therapeutics by 8.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after purchasing an additional 915 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.